Sulfasalazine suppository

Anti-inflammatory drugs. The pharmacological experiment of sulfasalazine suppository in rat immune ulcerative colitis model conducted a comparative observation on the effects of two routes of treating colitis: anal administration of suppositories and oral gavage of tablets. The results showed that the therapeutic effect of anal suppositories was significantly better than oral administration. (Absorption, distribution, elimination) Sulfasalazine suppositories enter the intestines and are decomposed into sulfapyridine and 5-aminosalicylic acid by intestinal bacteria. 5-aminosalicylic acid is eventually excreted from the body through feces. Sulfapyridine can be absorbed into the blood and finally excreted through urine. In addition to the original form of this product and sulfapyridine, its acetylated products and glucuronic acid conjugates can also be found in the blood. Sulfapyridine and its acetylated products can be excreted in the urine.

The main ingredient of this product is sulfasalazine.

This product is a yellow suppository made of a fatty matrix.

Used for inflammatory bowel diseases such as ulcerative colitis and nonspecific chronic colitis.

Rectal administration: Severe patients should take one pill each in the morning, afternoon and evening after defecation; moderate or mild patients should take one pill each in the morning and evening after defecation. After the symptoms are significantly improved, switch to a maintenance dose of one pill every night or every other night. The best time to take the medicine in the evening is before going to bed.

Not yet clear.

It is contraindicated in patients allergic to sulfonamides.

Precautions for children: Since sulfonamides can compete with bilirubin for binding sites on plasma proteins, and the acetyltransferase system of newborns is not fully developed, the free blood concentration of sulfonamides increases, which increases the risk of kernicterus. Therefore, this type of drug should be banned in newborns and children under 2 years old. Precautions for pregnancy and lactation: 1. Sulfonamides can cross the blood-placental barrier to the fetus, and animal experiments have found teratogenic effects. There is a lack of sufficient data in human studies, so pregnant women should not use them. 2. Sulfonamides can be secreted in breast milk, and the concentration in breast milk can reach about 50% to 100% of the maternal blood drug concentration. The drug may affect infants; the use of sulfonamides in newborns with glucose-6-phosphate dehydrogenase deficiency may cause hemolytic anemia. Therefore, it should be banned for breastfeeding women. Precautions for the elderly: Elderly patients have an increased chance of serious adverse reactions when using sulfonamides. For example, severe rash, bone marrow suppression and thrombocytopenia are common serious adverse reactions in the elderly. Therefore, elderly patients should avoid using them, and when there is an indication, the pros and cons should be weighed before deciding.

1. When used with urine alkalinizing drugs, the solubility of sulfonamides in alkaline urine can be enhanced, which increases excretion. 2. Para-aminobenzoic acid can replace sulfonamides and be taken up by bacteria, antagonizing the antibacterial effect of sulfonamides. Therefore, the two should not be used together. 3. When the following drugs are used in combination with sulfonamides, the latter can replace the protein binding sites of these drugs, or inhibit their metabolism, resulting in prolonged drug action or toxicity. Therefore, when these drugs are used in combination with sulfonamides, or after the use of sulfonamides, their dosages need to be adjusted. Such drugs include oral anticoagulants, oral hypoglycemic drugs, methotrexate, phenytoin sodium and thiopental sodium. 4. When bone marrow suppressive drugs are used in combination with sulfonamides, the adverse reactions of such drugs to the hematopoietic system may be enhanced. If there is an indication that the two types of drugs need to be used together, the possible toxic reactions should be closely observed. 5. Contraceptives (estrogens), long-term use with sulfonamides can reduce the reliability of contraception and increase the chance of extramenstrual bleeding. 6. When thrombolytic drugs are used in combination with sulfonamides, their potential toxic effects may be increased. 7. When hepatotoxic drugs are used in combination with sulfonamides, the incidence of hepatotoxicity may increase. Liver function should be monitored for such patients, especially those who have been taking the drugs for a long time and have a history of liver disease. 8. When photosensitizing drugs are used in combination with sulfonamides, additive photosensitization may occur. 9. Patients receiving sulfonamide treatment have an increased need for vitamin K. 10. Hexamethylenetetramine can decompose in acidic urine to produce formaldehyde, which can form insoluble precipitates with sulfonamides. This increases the risk of crystalluria, so the two drugs should not be used in combination. 11. Sulfonamides can replace the plasma protein binding site of phenylbutazone, and when the two are used in combination, the effect of phenylbutazone can be enhanced. 12. When sulfinpyrazone is used in combination with sulfonamides, the latter can reduce the latter's secretion from the renal tubules, and its blood drug concentration increases and lasts for a long time, thus producing toxicity. Therefore, the dosage of sulfonamides may need to be adjusted during or after the use of sulfinpyrazone. When the course of sulfinpyrazone is long, the blood concentration of sulfonamides should be monitored to help adjust the dosage and ensure safe use. 13. When used in combination with digitalis or folic acid, the latter's absorption is reduced and the blood concentration is reduced, so the effect and efficacy of digitalis must be observed at any time. 14. When used in combination with probenecid, it will reduce the excretion of sulfonamides in the renal tubules, causing the blood concentration of sulfonamides to increase, the effect is prolonged, and it is easy to be poisoned. 15. When used in combination with neomycin, neomycin inhibits intestinal flora, affects the decomposition of this product in the intestine, and reduces its effect.

Light-proof and airtight.

0.5g

24 months